The efficacy of low dose thalidomide in refractory/relapsed myeloma - A retrospective audit [2]

Leukemia and Lymphoma

Volumn 47, Issue 11, 2006, Pages 2409-2411

  Cherian, G ^a   Thomas, D W ^a   Rule, S A J ^a  

^a DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; MELPHALAN; METHYLPREDNISOLONE; PARAPROTEIN; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; CLINICAL ARTICLE; CONSTIPATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG POTENTIATION; FATIGUE; FEMALE; FOOT DISEASE; HAND PARESTHESIA; HUMAN; LETTER; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MEDICAL AUDIT; MULTIPLE MYELOMA; PARESTHESIA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RETINA VEIN; RETROSPECTIVE STUDY; SENSORY NEUROPATHY; SKIN TINGLING; SOMNOLENCE; TREATMENT RESPONSE; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RECURRENCE; RETROSPECTIVE STUDIES; THALIDOMIDE;

EID: 33751078295     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600879813     Document Type: Letter

References (12)

1. Singhal, S and Mehta, J and Desikan, R and Ayers, D and Roberson, P and Eddleman, P and (1999) Antitumour activity in thalidomide in refractory multiple myeloma N Engl J Med, 341, pp. 1565-1571.
2. Garcia-Sanz, R and Gonzalez-Fraile, M and Sierra, M and Lopez, C and Gonzales, M and Miguel, J. (2002) The combination of thalidomide, cyclophosphamide and dexamethasone is feasible and can be an option in relapsed/refractory multiple myeloma Haematol J, 3, pp. 43-48.
3. Barlogie, B and Tricot, G and Anaissie, E. (2001) Thalidomide in the management of multiple myeloma Sem Oncol, 28, pp. 577-582.
4. Yakoub-Agha, I and Attal, M and Dumontet, C and Delannoy, V and Moreau, P and Berthon, C and (2002) Thalidomide in patients with advanced multiple myeloma: A study of 83 patients Haematol J, 3, pp. 185-192.
5. Neben, K and Moehler, T and Benner, A and Kraemer, A and Egerer, G and Ho, A and (2002) Dose-dependent effects of thalidomide on overall survival of relapsed multiple myeloma Clin Cancer Res, 8, pp. 3377-3382.
6. Schey, S and Cavenagh, J and Johnson, R. (2003) A UK myeloma forum phase II study of thalidomide; long term follow up and recommendations for treatment Leuk Res, 27, pp. 909-914.
7. Kees, M and Dimou, G and Sillaber, C and Drach, J and Ackerman, J and Lechner, K and (2003) Low dose thalidomide in patients with relapsed or refractory multiple myeloma Leuk Lymphoma, 44, pp. 1943-1946.
8. Durie, G. (2002) Low dose thalidomide in myeloma Sem Oncol, 29(suppl 17), pp. 34-38.
9. Blade, J and Samson, D and Reece, D and Apperley, J and Bjorkstrand, B and Gahrton, G and (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high dose therapy and haemopoietic stem cell transplantation. Myeloma sub-committee of the EBMT Br J Haematol, 102, pp. 1115-1123.
10. Waage, A and Gimsing, P and Juliusson, G and Turesson, I and Gulbrandsen, N and Eriksson, T and (2004) Early response predicts thalidomide efficiency in patients with advanced multiple myeloma Br J Haematol, 125, pp. 149-155.
11. Offidani, M and Corvatta, L and Macroni, M and Malebra, L and Mele, A and Olivieri, A and (2004) Common and rare side-effects of low dose thalidomide in multiple myeloma: Focus on dose-minimizing peripheral neuropathy Eur J Haematol, 72, pp. 403-409.
12. Isoardo, G and Bergui, M and Durelli, L and Barbero, P and Bertola, A and Ciaramitaro, P and (2004) Thalidomide neuropathy: Clinical, electrophysiological and neuroradiological features Acta Neurol Scand Mar, 109, pp. 188-193.